36886This is how low salary people should avail credit card benefits!

The Serum Institute of India said it will start export of Covid-19 vaccine by year-end

India’s arsenal of vaccines consists of SII-AstraZeneca-made Covishield, Bharat Biotech’s Covaxin and Russia’s Sputnik.

The Serum Institute of India on Tuesday said has delivered more than 200 million doses to date and will start export of Covid-19 vaccine by year-end.

“SII has delivered more than 200 million doses, even though we received EUA two months after the US pharma companies. If we look at total doses produced and delivered, we rank amongst the top three in the world. We continue to scale up manufacturing and prioritise India. We also hope to start delivering to COVAX and other countries by the end of this year,” the vaccine manufacturer said in a statement on its Twitter handle.

Amid reports of vaccine shortage in the country, the Serum Institute of India said: “We’re amongst 2 most populous countries in the world, a vaccination drive for such large population can’t be completed within 2-3 months, as several factors & challenges are involved. It’d take 2-3 years for the entire world population to get fully vaccinated.”

“We would like to reiterate that we have never exported vaccines at the cost of the people in India and remain committed to doing everything we can in the support of the vaccination drive in the country,” it added.

The vaccine manufacturer also highlighted its global commitment to provide vaccines.

“We must also understand that this pandemic is not limited by geographic or political boundaries. We will not be safe till everyone globally is able to defeat this virus at a global scale. Further, as part of our global alliances, we also had commitments to COVAX, so that they could distribute the vaccines globally to end the pandemic,” SII said.

Published: May 18, 2021, 19:19 IST
Exit mobile version